Introduction {#s1}
============

Interaction of GABA with GABA type A (GABA~A~) receptors enables fast inhibitory neurotransmission in the mammalian brain ([@B3]; [@B29]; [@B39]). Like other members of the family of pentameric ligand-gated ion channels, GABA~A~ receptors are constituted by pseudosymmetrical assembly of five identical or homologous subunits forming a chloride-conducting ion ([@B26]). The human genome comprises genes encoding for 19 different GABA~A~ receptor subunits \[*α*1-6, *β*1-3, *γ*1-3, *δ*, *ε*, *ρ*1-3, *π*, and *θ* ([@B40])\], theoretically allowing the formation of multiple GABA~A~ receptor subtypes. The receptor's subunit composition determines its pharmacological properties including agonist sensitivity as well as its sensitivity for drugs ([@B3]; [@B39]). In addition, the highly specific cellular and subcellular distribution of GABA~A~ receptor subunits/subtypes ([@B30]; [@B38]; [@B29]) and in particular the assignment of therapeutic effects of commonly applied GABA~A~ receptor modulators such as benzodiazepines (e.g., [@B28]; [@B33]; [@B34]; [@B11], [@B12]; [@B35]) or anesthetics ([@B17]) to single GABA~A~ receptor subunits raises the possibility of developing drugs selectively targeting specific brain circuits. Such subunit-selective GABA~A~ receptor modulators are predicted to display the desired therapeutic effects with reduced side effects.

Valerenic acid (VA), a sesquiterpenoid compound found in common *Valerian*, selectively modulates *γ*-aminobutyric acid type A (GABA~A~) receptors containing *β*2- or *β*3-subunits, while displaying only negligible effects on GABA~A~ receptors incorporating *β*1-subunits ([@B19]; [@B4]). In vivo, VA induces anxiolytic ([@B4]; [@B20]; [@B14]) and anticonvulsive ([@B14]) effects. Most notably, VA does not significantly reduce locomotor activity even at high doses ([@B20]).

These findings combined with a promising pharmacokinetic profile ([@B36]) make VA an interesting drug candidate. Previously, we reported more pronounced anxiolytic and/or anticonvulsive effects by selected VA amide ([@B20]) and ester derivatives ([@B14]). In contrast to VA ester derivatives that are significantly less active in vitro and thus might act as prodrugs ([@B14]), both VA amide derivatives ([@B20]; [@B21]) as well as VA's nitrile and tetrazole analogs ([@B21]) efficaciously enhance GABA-induced chloride currents (I~GABA~) through receptors composed of *α*1*β*3 subunits ([@B20]) or *α*1*β*2*γ*2S ([@B21]) expressed in *Xenopus* oocytes.

Therefore, to evaluate the potential of VA derivatives as scaffold for the development of novel anticonvulsants, we extended these previous studies by determining *β*-subunit dependency of I~GABA~ modulation by a small focused library of VA derivatives in oocytes expressing *α*1*β*1*γ*2S, *α*1*β*2*γ*2S, or *α*1*β*3*γ*2S receptors followed by an in vivo investigation of their effects on pentylenetetrazole (PTZ)-induced seizure threshold and locomotor activity in male C57BL/6N mice.

Our study shows that VA's amide (VA-A) and methylamide (VA-MA) derivatives, respectively, modulating *α*1*β*3*γ*2S GABA~A~ receptors more efficaciously than VA displayed also significantly more pronounced elevation of PTZ-induced seizure threshold. In addition, VA's tetrazole derivative (VA-TET), an efficacious VA derivative already reported in a preceding study by [@B21] modulating *α*1*β*3*γ*2S receptors more potently than VA, displayed anticonvulsive effects at lower doses than the VA. In contrast, unselective VA derivatives such VA-ethylamide (VA-EA) or VA-diethylamide (VA-DEA) displayed anticonvulsive effects only at high doses (30 mg/kg) or did not show any effects on either PTZ-induced seizure threshold or locomotion (VA-dimethylamide, VA-DEA).

Materials and Methods {#s2}
=====================

 {#s3}

### Animals and Animal Welfare. {#s4}

All experiments involving animals were approved by the Austrian Animal Experimentation Ethics Board in compliance with the European convention for the protection of vertebrate animals used for experimental and other scientific purposes ETS no.: 123, which is in line with the EU Directive 2010/63/EU (GZ 66.006/0019-C/GT/2007, GZ 66.006/0008-II/10b/2008 and GZ 66.006/0009-II/10b/2010). Every effort was taken to minimize the number of animals used.

Female *Xenopus laevis* frogs were purchased from NASCO (Fort Atkinson, WI) and kept in groups in temperature-controlled, continuous-flow water tanks (20 ± 1°C). Male mice (C57BL/6N) were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice were group housed (maximum 5 mice per type IIL cage) with free access to food and water. At least 24 hours before the commencement of experiments, they were transferred to the testing facility, continuing ad libitum access to food and water.

The temperature in the holding (for mice and frogs) and testing facilities was fixed to 22 ± 2°C; the humidity ranged between 40 and 60%; a 12-hour light-dark cycle was in operation (lights on from 0700 to 1900).

### Chemicals. {#s5}

All chemicals used in this study were obtained from Sigma Aldrich (Vienna, Austria) except where stated otherwise. VA was purchased from HWI Pharma Solutions (Rülzheim, Germany). VA derivatives (structural formulae are depicted in [Fig. 1](#F1){ref-type="fig"}) were synthesized as previously described: description of the syntheses of VA-A \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-2-methylacrylamide)\], VA-MA \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N*,2-dimethylacrylamide)\], VA-DMA \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N,N*,2-trimethylacrylamide)\], VA-EA \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N*-ethyl-2-methylacrylamide)\], VA-DEA \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N*,*N*-diethyl-2-methylacrylamide)\] can be found in ([@B20]) and for VA-TET \[5-((*E*)-1-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)prop-1-en-2-yl)-1*H*-tetrazole)\] and VA-CN \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-2-methylacrylonitrile)\], see [@B21]. Stock solutions (100 mM for in vitro experiments and 1 mg/10 *µ*l for in vivo experiments, respectively) were prepared in 100% dimethylsulfoxide (DMSO). VA and its derivatives were used up to a concentration of 500 *µ*M in in vitro experiments. Equal amounts of DMSO were present in control and compound-containing solutions. The maximum DMSO concentration in the bath (0.5%) did not affect I~GABA~. For in vivo experiments, working concentrations were adjusted by dilution with 0.9% sodium chloride; the final concentration of DMSO was fixed to 10% including control solutions. To enhance solubility of the compound, Tween 80 (3% final concentration) was added to all solutions. pH was adjusted to 7.2--7.4 with 1 M sodium hydroxide. All solutions were freshly prepared every day before experiments.

![VA and VA derivatives. Structural formulae of studied valerenic acid (VA) and VA derivatives are illustrated.](jpet.116.232983f1){#F1}

### Expression and Functional Characterization of GABA~A~ Receptors. {#s6}

Preparation of stage V-VI oocytes from *Xenopus laevis* (NASCO, Fort Atkinson), synthesis of capped off run-off poly(A^+^) rat cRNA transcripts from linearized cDNA templates (pCMV vector) was performed as described elsewhere ([@B18]). Briefly, female *Xenopus laevis* were anesthetized by exposing them for 15 min to a 0.2% solution of MS-222 (methane sulfonate salt of 3-aminobenzoic acid ethyl ester) before surgically removing parts of the ovaries. Follicle membranes from isolated oocytes were enzymatically digested with 2 mg/ml collagenase (Type 1A). Oocytes were stored at 18°C in ND96 solution ([@B25]). After isolation, oocytes were injected with about 10--50 nl of nuclease-free water containing the different rat cRNAs (100--2000 ng/*μ*l/subunit). For expression of *α*1*β*3*γ*2S and *α*1*β*2*γ*2S receptors, respectively, cRNAs were mixed in a ratio of 1:1:10 ([@B5]); to avoid formation of homooligomeric *β*1-receptors in the case of *α*1*β*1*γ*2S, a ratio of 3:1:10 was used ([@B22]). Electrophysiological experiments were done using the two-microelectrode voltage-clamp technique at a holding potential of −70 mV, making use of a TURBO TEC 01C amplifier (npi electronic, Tamm, Germany) and an Axon Digidata 1322A interface (Molecular Devices, Sunnyvale, CA). Data acquisition was carried out using pCLAMP v.9.2 (Molecular Devices). The bath solution contained 90 mM NaCl, 1 mM KCl, 1 mM MgCl~2~, 1 mM CaCl~2~, and 5 mM HEPES (pH 7.4). Microelectrodes were filled with 2 M KCl and had resistances between 1 and 3 MΩ.

### Perfusion System. {#s7}

GABA and drugs were applied by means of a fast perfusion system; drug or control solutions were applied by means of a TECAN Miniprep 60 permitting automation of the experiments \[([@B2]) ScreeningTool, npi electronic\]. To elicit I~GABA~, the chamber was perfused with 120 *µ*l of GABA-containing solution at a volume rate between 300 and 1000 *µ*l/s. The I~GABA~ rise time ranged between 100 and 250 ms ([@B18]). To account for possible slow recovery from increasing levels of desensitization in the presence of high compound concentrations, the duration of washout periods was extended stepwise, i.e., 1 min (GABA EC~3-7~) to 1.5 min (coapplication of GABA EC~3-7~ in the presence ≤1 *µ*M compound) to 2.5 min (coapplication of GABA EC~3-7~ in the presence of ≤10 *µ*M compound) to 5 min (coapplication of GABA EC~3-7~ and ≤100 *µ*M compound) to 15 min (GABA EC~3-7~ in the presence of 300--500 *µ*M compound). Oocytes with maximal current amplitudes \>5 *µ*A were discarded to exclude voltage-clamp errors.

### Analyzing Concentration-response Curves. {#s8}

Enhancement of chloride currents (I~GABA~) by VA and VA derivatives was measured at a GABA concentration eliciting between 3 and 7% of the maximal current amplitude (EC~3--7~). The EC~3-7~ was determined at the beginning of the experiment for each oocyte by application of 1 mM GABA followed by submaximal GABA concentrations. I~GABA~ enhancement was defined as \[I~(GABA+Comp)~/I~GABA~) − 1\], where I~(GABA+Comp)~ is the current response in the presence of compound and I~GABA~ is the control GABA current. Concentration-response curves were generated, and the data were fitted by nonlinear regression analysis using Origin software (OriginLab Corporation, Northampton, MA). Data were fitted to the following equation:In this equation, k corresponds to the EC~50~ value, x values are logs of concentration, and n~H~ stands for the Hill coefficient. Each data point represents the mean ± S.E.M. from ≥3 oocytes and ≥2 oocyte batches.

### In Vivo Characterization of VA Derivatives. {#s9}

Only male C57BL/6N mice (age 3--6 months) were used in the tests described below. Intraperitoneal injection of control or compound-containing solutions was done 30 min before the test. Indicated doses in the *[Results](#s13){ref-type="sec"}* and *[Discussion](#s18){ref-type="sec"}* represent milligrams per kilogram body weight.

### Seizure Threshold. {#s10}

Seizure threshold was determined by pentylenetetrazole (PTZ) tail-vein infusion on freely moving animals at a rate of 100 *µ*l/min (10 mg/ml PTZ in saline, pH = 7.4). Infusion was stopped when animals displayed generalized clonic seizures. Animals were immediately killed by cervical displacement after onset of seizures. The seizure threshold dose was calculated from the infused dose in relation to body weight (mg/kg).

### Open-field Test. {#s11}

Exploration of a novel environment was tested over 10 min in a 50 × 50 cm box built from gray PVC equipped with infrared beams. Illumination intensity was set to 150 lux in the center. Animals' motor activity was analyzed using ActiMot-2 equipment and software (TSE-systems, Bad Homburg, Germany).

### Statistical Analysis. {#s12}

Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by a post hoc mean comparison with Bonferroni (OriginLab Corporation or GraphPad, La Jolla, CA). *P* values of \<0.05 were accepted as statistically significant. All data are given as mean ± S.E.M.

Results {#s13}
=======

 {#s14}

### Determination of *β*-Subunit Dependency of I~GABA~ Modulation by Valerenic Acid and VA Derivatives. {#s15}

GABA~A~ receptors composed of *α*1*β*1*γ*2S~,~ *α*1*β*2*γ*2S, or *α*1*β*3*γ*2S subunits were expressed in *Xenopus laevis* oocytes, and modulation of GABA-induced chloride currents (I~GABA~, GABA EC~3-7~) by VA and seven carboxyl-group modified derivatives was analyzed by means of the two-microelectrode voltage-clamp technique (for structural formulae of investigated VA derivatives, see [Fig. 1](#F1){ref-type="fig"}). Amidation of VA (VA-amide, VA-A) resulted in significantly stronger I~GABA~ enhancement of both *α*1*β*3*γ*2S (VA-A: E~max~ = 972 ± 69%, *n* = 6 versus VA: E~max~ = 632 ± 88%, *n* = 9, *P* \< 0.01) and *α*1*β*2*γ*2S receptors (VA-A: E~max~ = 1119 ± 72%, *n* = 6 versus VA: E~max~ = 721 ± 68%, *n* = 5, *P* \< 0.05, compare [Fig. 2, A and C](#F2){ref-type="fig"}). Subsequent monomethylation of VA-A (VA-mono-methylamide, VA-MA) also significantly increased I~GABA~ enhancement of *α*1*β*3*γ*2S receptors (VA-MA: E~max~ = 1043 ± 57%, *n* = 5, *P* \< 0.01, [Fig. 2E](#F2){ref-type="fig"}) compared with VA; in addition, a strong trend toward more pronounced I~GABA~ enhancement of *α*1*β*2*γ*2S channels by VA-MA was observed; however, this effect did not reach statistical significance (VA-MA: E~max~ = 917 ± 36%, *n* = 3, *P* \> 0.05, [Fig. 2E](#F2){ref-type="fig"}). Modulation of I~GABA~ through *β*1-containing receptors by VA-A and VA-MA did not significantly differ, although slightly enhanced, from I~GABA~ enhancement by VA \[*α*1*β*1*γ*2S: VA: E~max~ = 111 ± 16%, *n* = 8 versus VA-A: E~max~ = 218 ± 78%, *n* = 6; VA-MA: E~max~ = 387 ± 56%, *n* = 5; *P* \> 0.05; compare [Fig. 2, A, C, and E](#F2){ref-type="fig"}; see also [Table 1](#T1){ref-type="table"}, see also ([@B20]; [@B21]) for VA-A enhancement of *α*1*β*1-3, *α*1*β*2*γ*2S, and *α*3*β*3*γ*2S and VA-MA enhancement of *α*1*β*3 and *α*1*β*2*γ*2S receptors\].

![β-Subunit-dependent I~GABA~ enhancement by VA and VA derivatives. Concentration-dependent modulation of GABA~A~ receptors composed of α1β3γ2S (dashed line), α1β2γ2S (▪), and α1β1γ2S (♦) subunits by (A) VA (data for enhancement of α1β3γ2S receptors taken from ([@B24]), (C) VA-A, (E) VA-MA, and (G) VA-TET. Data were fitted by nonlinear regression as described in Materials and Methods. Maximal potentiation of I~GABA~ (E~max~), EC~50~ values, Hill-coefficients (n~H~) and number of experiments for each compound on α1β1γ2S, α1β2γ2S and α1β3γ2S receptors are summarized in [Table 1](#T1){ref-type="table"}. Each data point represents a mean ± S.E.M from at least 3 different oocytes from 2 different frog batches. I~GABA~ potentiation at 300 *µ*M (α1β3γ2S receptors) for VA and VA-A, respectively, was excluded from the fit. Typical traces for the enhancement of GABA-induced chloride currents (I~GABA~, EC~3-7~, single bar) by 10 *µ*M of (B) VA, (D) VA-A, (F) VA-MA, and (H) VA-TET (double bar; indicating coapplication of GABA and compound) at the indicated GABA~A~ receptor subtype are illustrated.](jpet.116.232983f2){#F2}

###### 

Summary of pharmacological parameters of I~GABA~ enhancement through *α*~1~*β*~1~*γ*~2S~, *α*~1~*β*~2~*γ*~2S~, and *α*~1~*β*~3~*γ*~2S~ receptors including maximal I~GABA~ enhancement (E~max~), half-maximal effective concentrations (EC~50~), Hill-coefficients (n~H~), and number of experiments for each compound at the tested subunit combinations

Data for I~GABA~ enhancement of *α*1*β*3*γ*2S receptors by VA at GABA EC~3-7~ concentrations taken from [@B24].

                  E~max~ (%)   EC~50~ ()     n~H~        *n*
  --------------- ------------ ------------- ----------- -----
                  *%*          *µM*                      
  *α*1*β*1*γ*2S                                          
   VA             111 ± 16     74.4 ± 19.3   1.6 ± 0.5   8
   VA-A           218 ± 78     66.6 ± 34.6   1.8 ± 0.6   6
   VA-MA          387 ± 56     58.1 ± 16.5   1.6 ± 0.3   5
   VA-DMA         305 ± 67     52.5 ± 20.1   1.7 ± 0.5   6
   VA-EA          458 ± 124    51.4 ± 19.8   1.6 ± 0.3   5
   VA-DEA         318 ± 84     97.2 ± 33.8   1.8 ± 0.3   7
   VA-CN          55 ± 14      73.0 ± 38.7   1.7 ± 0.7   7
   VA-TET         176 ± 43     23.5 ± 10.9   1.8 ± 0.6   7
  *α*1*β*2*γ*2S                                          
   VA             721 ± 68     23.1 ± 4.2    1.4 ± 0.2   5
   VA-A           1119 ± 72    14.0 ± 2.2    1.4 ± 0.2   6
   VA-MA          917 ± 36     9.1 ± 1.4     1.5 ± 0.1   3
   VA-DMA         594 ± 36     63.9 ± 23.7   1.3 ± 0.2   5
   VA-EA          554 ± 49     11.0 ± 3.6    1.6 ± 0.3   3
   VA-DEA         573 ± 33     54.4 ± 11.1   1.6 ± 0.3   5
   VA-CN          765 ± 117    56.5 ± 13.3   2.5 ± 0.7   4
   VA-TET         1091 ± 87    34.1 ± 6.3    1.0 ± 0.1   5
  *α*1*β*3*γ*2S                                          
   VA             632 ± 88     20.2 ± 5.2    1.5 ± 0.3   9
   VA-A           972 ± 69     7.5 ± 1.8     1.5 ± 0.2   6
   VA-MA          1043 ± 57    12.7 ± 0.9    1.5 ± 0.1   6
   VA-DMA         415 ± 61     48.0 ± 16.0   1.4 ± 0.2   6
   VA-EA          677 ± 64     27.2 ± 6.7    1.3 ± 0.2   12
   VA-DEA         374 ± 102    80.8 ± 31.3   1.9 ± 0.5   5
   VA-CN          522 ± 114    42.4 ± 15.8   2.1 ± 0.8   7
   VA-TET         668 ± 57     6.0 ± 1.0     1.1 ± 0.1   8

Replacement of the carboxyl moiety by the bioisosteric tetrazole group (VA-TET) significantly increased efficacy on *α*1*β*2*γ*2S (E~max~ = 1091 ± 87%, *n* = 5, *P* \< 0.05, [Fig. 2G](#F2){ref-type="fig"}) receptors, although with a slightly reduced potency compared with VA, whereas efficacy of I~GABA~ enhancement on *α*1*β*1*γ*2S (E~max~ = 176 ± 43%, *n* = 7) and *α*1*β*3*γ*2S (E~max~ = 668 ± 57%, *n* = 8; [Fig. 2G](#F2){ref-type="fig"}) receptors did not differ from that of the parent compound. However, most remarkably, VA-TET displayed an approximately threefold increased potency on *β*3-containing receptors compared with VA (VA: EC~50~ = 20.2 ± 5.2 *µ*M; *n* = 9 versus VA-TET: EC~50~ = 6.0 ± 1.0 *µ*M; *n* = 8; see [Fig. 2](#F2){ref-type="fig"} for representative current traces for *β*-subunit-dependent I~GABA~ enhancement by ([Fig. 2B](#F2){ref-type="fig"}) VA, ([Fig. 2D](#F2){ref-type="fig"}) VA-A, ([Fig. 2F](#F2){ref-type="fig"}) VA-MA, and ([Fig. 2H](#F2){ref-type="fig"}) VA-TET; data for I~GABA~ enhancement of GABA~A~ channels composed of *α*1*β*3*γ*2S subunits by VA are taken from [@B24]; see also the effect of VA-TET applied at low GABA concentrations (EC~1-4~) in [@B21].

Similarly, substituting VA's carboxyl group by a nitrile (VA nitrile, VA-CN) did not affect *β*2/3-subunit-selective I~GABA~ potentiation: I~GABA~ enhancement by VA-CN through *α*1*β*1*γ*2S (E~max~ = 55 ± 14%, *n* = 7)~,~ *α*1*β*2*γ*2S (E~max~ = 765 ± 117%, *n* = 4), and *α*1*β*3*γ*2S (E~max~ = 522 ± 114%, *n* = 7) channels, respectively, was similar to that of VA; however, a trend toward slightly decreased potency on *β*2- and *β*3-subunit-containing receptors was observed \[see [Fig. 3A](#F3){ref-type="fig"}; see also [@B21] for I~GABA~ enhancement through *α*1*β*2*γ*2S channels by VA-CN at GABA EC~1-4~ concentrations\].

![β-Subunit-dependent I~GABA~ modulation by VA derivatives. Concentration-response curves for the I~GABA~ enhancement through (●) *α*1*β*3*γ*2S, (▪) *α*1*β*2*γ*2S, and (♦) *α*1*β*1*γ*2S channels by VA derivatives (A) VA-CN, (C) VA-EA, (E) VA-DMA, and (G) VA-DEA. Data were fitted by nonlinear regression as described in Materials and Methods. Maximal potentiation of I~GABA~ (E~max~), EC~50~ values, Hill-coefficients (n~H~), and number of experiments for each compound on *α*1*β*1*γ*2S, *α*1*β*2*γ*2S, and *α*1*β*3*γ*2S receptors are summarized in [Table 1](#T1){ref-type="table"}. Each data point represents a mean ± S.E.M. from at least 3 different oocytes from 2 different frog batches. Typical current traces for the enhancement of GABA-induced chloride currents (I~GABA~, EC~3-7~, single bar) by 10 *µ*M of (B) VA-CN, (D) VA-EA, (F) VA-DMA, and (H) VA-DEA (double bar; indicating coapplication of GABA and compound) at the indicated GABA~A~ receptor subtype are illustrated.](jpet.116.232983f3){#F3}

In contrast, introducing bulkier residues such as monoethylamide (VA-EA), dimethylamide (VA-DMA), or diethylamide (VA-DEA) significantly elevated efficacy on *β*~1~-containing receptors compared with VA (VA-EA: E~max~ = 458 ± 124%, *n* = 5, [Fig. 3B](#F3){ref-type="fig"}; VA-DMA: E~max~ = 305 ± 67%, *n* = 6, [Fig. 3C](#F3){ref-type="fig"}; VA-DEA: E~max~ = 318 ± 84%, *n* = 7, [Fig. 3D](#F3){ref-type="fig"}; *P* \> 0.05), whereas the estimated efficacies on *β*2- and *β*3-containing receptors were comparable to VA, indicating a loss of subunit selectivity ([Figs. 3B--D](#F3){ref-type="fig"}). Data for maximal I~GABA~ enhancement (E~max~, %), EC~50~ (*µ*M), Hill-coefficients (n~H~), and number of experiments (*n*) for all receptor subunit compositions tested are summarized in [Table 1](#T1){ref-type="table"}.

### Effects of VA and VA Derivatives on Pentylenetetrazole-Induced Seizure Threshold. {#s16}

We recently reported that the elevation of PTZ-induced seizure threshold by VA (3 mg/kg body weight) is most pronounced 30 min after application ([@B14]). In the present study, dose-dependent effects of VA on seizure threshold were determined. As depicted in [Fig. 4A](#F4){ref-type="fig"}, VA did not alter seizure threshold at doses \<3 mg/kg body weight; in contrast, pronounced seizure threshold elevation was observed after application of VA at a dose of 3 or 10 mg/kg body weight \[control: 40.4 ± 1.4 mg/kg PTZ, *n* = 6 versus VA 3 mg/kg: 47.7 ± 1.4 mg/kg PTZ, *n* = 4, *P* \< 0.01 and VA 10 mg/kg: 49.0±1.8 mg/kg PTZ, *n* = 4; *P* \< 0.05, respectively; data for seizure threshold elevation by VA at a dose of 3 mg/kg body weight are taken from [@B14]\]. Seizure threshold of animals treated with VA at a dose of 30 mg/kg body weight did not differ significantly from diluent-treated control animals (30 mg/kg VA: 43.4 ± 1.8 mg/kg PTZ, *n* = 3, *P* \> 0.05; [Fig. 4A](#F4){ref-type="fig"}). Compared with VA, VA-A exerted significantly stronger anticonvulsive activity at doses ≥3 mg/kg (see [Fig. 4B](#F4){ref-type="fig"}, VA-A 3 mg/kg: 57.9 ± 1.9 mg/kg PTZ, *n* = 4; VA-A 10 mg/kg: 55.4 ± 0.7 mg/kg PTZ, *n* = 4, *P* \< 0.001). Like VA, VA-A also displayed a trend toward reduced activity at higher doses (30 mg/kg); however, in contrast to VA, it still retained its anticonvulsive potential ([Fig. 4B](#F4){ref-type="fig"}, VA-A 30 mg/kg: 50.6 ± 2.2 mg/kg PTZ, *n* = 3, *P* \< 0.01).

![Anticonvulsive effects of VA and VA derivatives. Elevation of seizure threshold upon tail-vein infusion of PTZ 30 min after intraperitoneal application of (A) VA is illustrated. The dotted line represents the averaged seizure threshold of saline-treated control animals. Effect on PTZ-induced seizure threshold 30 min after intraperitoneal application by the VA derivatives (B) VA-A, (C) VA-TET, (D) VA-MA, (E) VA-DMA, (F) VA-EA, (G) VA-DEA, and (H) VA-CN is compared with VA (dashed line, ○) and control animals (dotted line). Each data point represents a mean ± S.E.M from at least 3 mice. Statistical significance (*P* values \< 0.05 were accepted as significant; \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001) against VA was calculated by one-way ANOVA followed by a Bonferroni post hoc mean comparison.](jpet.116.232983f4){#F4}

A similar (but left-shifted) bell-shaped dose-response curve on PTZ-induced seizure threshold was observed for VA-TET; at a dose of 0.3 mg/kg bodyweight ([Fig. 4C](#F4){ref-type="fig"}: VA-TET 0.3 mg/kg: 47.3 ± 0.5mg/kg PTZ, *n* = 5, *P* \< 0.05) VA-TET's anticonvulsive activity was comparable to that of VA at 10-fold higher doses (3 mg/kg), indicating a significantly increased potency. However, VA-TET lost its anticonvulsive properties at doses ≥1 mg/kg. The methylated VA-A derivative (VA-MA) induced the most pronounced increase in seizure threshold of all tested compounds; first significant effects were observed at a dose of 10 mg/kg ([Fig. 4D](#F4){ref-type="fig"}: VA-MA 10 mg/kg: 50.4±1.4 mg/kg PTZ, *n* = 4, *P* \< 0.001). In contrast to VA, VA-A, and VA-TET, application of higher doses (i.e., 30 mg/kg) VA-MA resulted in an even further elevated seizure threshold (VA-MA 30 mg/kg: 63.6 ± 2.5 mg/kg PTZ, *n* = 3, *P* \< 0.001).

As shown in [Fig. 4, F, G, and H](#F4){ref-type="fig"}, higher doses of VA-EA, VA-DEA, and VA-CN were required for seizure threshold elevation similar to that of VA (compare VA 3 mg/kg: 47.7 ± 1.4 mg/kg PTZ, *n* = 4, [Fig. 4A](#F4){ref-type="fig"} versus VA-EA 30 mg/kg: 55.6 ± 0.4 mg/kg PTZ, *n* = 4, [Fig. 4F](#F4){ref-type="fig"} versus VA-DEA: 30 mg/kg: 48.7±1.7 mg/kg PTZ, *n* = 3, [Fig. 4G](#F4){ref-type="fig"} versus VA-CN 10 mg/kg: 51.1 ± 0.6 mg/kg PTZ, *n* = 3, [Fig. 4H](#F4){ref-type="fig"}).

Seizure threshold of mice treated with VA-DMA ([Fig. 4E](#F4){ref-type="fig"}) did not significantly differ at any tested dose from diluent-treated control littermates.

### Effects of VA and Derivatives on Locomotion in the Open Field Test. {#s17}

As illustrated in [Fig. 5A](#F5){ref-type="fig"}, locomotor activity of VA-treated mice did not differ significantly from control animals at any tested dose in the open field test (control: 38.3 ± 1.5 m, *n* = 25 versus VA 1 mg/kg: 34.9 ± 1.3 m, *n* = 12 versus VA 3 mg/kg: 38.7 ± 2.1 m, *n* = 16 versus VA 10 mg/kg: 38.0 ± 1.4 m, *n* = 16 versus VA 30 mg/kg: 37.6 ± 2.5 m, *n* = 16).

![Effects on locomotion by VA and VA derivatives in the open-field test (OF) test. Black bars indicate the total distance covered in the OF test 30 minutes after intraperitoneal application of (A) VA, (B) VA-A, (C) VA-TET, (D) VA-MA, (E) VA-CN, (F) VA-DMA, (G) VA-EA, and (H) (VA-DEA) at the indicated doses compared with saline-treated control animals (white bars in all panels). Each bar represents a mean ± S.E.M. from at least 10 different mice. Statistical significance (*P* values \< 0.05 were accepted as significant; \**P* \< 0.05 and \*\*\**P* \< 0.001) against saline-treated control animals was calculated by one-way ANOVA followed by a Bonferroni post hoc mean comparison.](jpet.116.232983f5){#F5}

Application of VA derivative VA-A at doses of 1 and 3 mg/kg, respectively, did also not affect the total distance covered compared with control littermates; however, reduced locomotor activity in the open-field test was measured after application of VA-A at doses ≥10 mg/kg (control: 38.3 ± 1.5 m, *n* = 25 versus VA-A 10 mg/kg: 29.9 ± 2.6 m, *n* = 11, *P* \< 0.05 versus VA-A 30 mg/kg: 23.5±2.2 m, *n* = 18, *P* \< 0.001; see [Fig. 5B](#F5){ref-type="fig"}).

Like VA-A, derivatives VA-TET ([Fig. 5C](#F5){ref-type="fig"}), VA-MA ([Fig. 5D](#F5){ref-type="fig"}), and VA-CN ([Fig. 5E](#F5){ref-type="fig"}) did not affect locomotor activity at low doses (≤10 mg/kg); however, at higher doses reduced ambulation was observed for these compounds (control: 38.3 ± 1.5 m, *n* = 25 versus VA-TET 30 mg/kg: 19.2 ± 2.1 m, *n* = 13, *P* \< 0.001 versus VA-MA 30 mg/kg: 29.7 ± 2.0 m, *n* = 12, *P* \< 0.01 versus VA-CN 30 mg/kg: 31.5±1.5 m, *n* = 14, *P* \< 0.05).

Finally, analysis of total distance did not reveal any significantly different behavior of animals treated with any dose of the *β*-subunit-unselective VA derivatives VA-DMA ([Fig. 5F](#F5){ref-type="fig"}), VA-EA ([Fig. 5G](#F5){ref-type="fig"}), and VA-DEA ([Fig. 5H](#F5){ref-type="fig"}) or diluent-treated control animals.

Discussion {#s18}
==========

Subunit-selective GABA~A~ receptor modulators represent interesting lead structures for drug development. The natural compound VA selectively modulates GABA~A~ receptors containing either *β*2- or *β*3-subunits, with only residual modulatory activity on GABA~A~ receptors incorporating *β*1-subunits at high concentrations ([@B19]; [@B4]). As opposed to benzodiazepines, VA and also its derivatives do not interact with the benzodiazepine binding site \[i.e., I~GABA~ enhancement by VA and VA derivatives does not require the presence of a *γ*2S-subunit and VA's modulatory action cannot be blocked by the benzodiazepine site antagonist flumazenil ([@B19], [@B20])\]. This selectivity profile combined with pronounced anticonvulsive effects ([@B14]) accompanied by anxiolytic activity ([@B20]; [@B14]) and devoid of significant impairment of locomotor activity suggesting lack of sedative side effects makes VA and potentially also its derivatives promising drug candidates.

Previously, we and others have reported more efficacious and/or potent modulation of GABA~A~ receptors expressed in *Xenopus* oocytes by carboxyl-modified VA derivatives ([@B20]; [@B21]). Furthermore, more pronounced anxiolytic effects by the amide derivative of VA (VA-A) ([@B20]) as well as stronger anxiolytic and anticonvulsive effects of VA ester derivatives compared with VA were observed ([@B14]).

To further evaluate the potential of VA and carboxyl-modified derivatives (for structural formulae, see [Fig. 1](#F1){ref-type="fig"}) as scaffolds for the development of novel anticonvulsants with limited impairment of locomotor activity, we extended previous in vitro studies of these compounds ([@B20]; [@B21]) by determining their *β*-subunit dependency of I~GABA~ modulation (*α*1*β*1*γ*2S, *α*1*β*2*γ*2S, *α*1*β*3*γ*2S) followed by a subsequent analysis of their effects on PTZ-induced seizure threshold and locomotion.

 {#s19}

### VA Derivatization Has Dual Effects on *β*-Subunit Selectivity. {#s20}

An interesting finding of the present study was that VA derivatization had, depending on the substituent introduced, dual effects on *β*-subunit selectivity; amidation of VA (VA-A) as well as monomethylation of the amide (VA-MA), respectively, strongly increased efficacy of I~GABA~ enhancement of *β*2- and *β*3-containing receptors compared with VA (compare [Fig. 2, A, C, and E](#F2){ref-type="fig"}), whereas efficacy of I~GABA~ enhancement through *β*1-containing receptors did not differ significantly from that of VA, thus boosting *β*-subunit selectivity. Replacing the carboxyl-function by a tetrazole group (VA-TET) significantly increased potency of I~GABA~ enhancement through *β*3-containing receptors and efficacy of I~GABA~ of *β*2-containing receptors, whereas modulation of *β*1-receptors by VA-TET was comparable to that of VA (compare [Fig. 2, A and C](#F2){ref-type="fig"}). Intriguingly, this structural modification (replacement of the carboxyl-group by a tetrazole moiety) altered current kinetics (see [Fig. 2H](#F2){ref-type="fig"} for typical I~GABA~ in the presence of 10 *μ*M VA-TET); compared with I~GABA~ modulated by any of the other studied VA derivatives ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, right panels), receptor activation in the presence of VA-TET appeared to be slowed (see longer time required to reach peak currents), and, in addition, current desensitization could not be observed even at high drug concentrations. The parent compound VA, at concentrations ≥30*μ*M, has been reported to directly activate GABA~A~ channels in the absence of GABA (see [@B19]). Compared with I~GABA~, both activation and deactivation rates of these VA-induced currents were remarkably slower. We speculate that VA-TET, representing the more potent bioisoster of VA in terms of modulatory activity (see [Table 1](#T1){ref-type="table"} and [Fig. 2, A and G](#F2){ref-type="fig"}), might also directly activate the channel like VA at lower concentrations and that the observed kinetics reflect a combination of direct activation and modulatory activity. However, these differences in current kinetics warrant further investigations.

Substituting the carboxyl-group by a nitrile function (VA-CN) resulted in a similar *β*2/3-subunit dependency as observed for VA ([Fig. 3A](#F3){ref-type="fig"}). In contrast, introduction of bulkier residues such as dimethylamide (VA-DMA), ethylamide (VA-EA), or diethylamide (VA-DEA) did not alter efficacy or potency of I~GABA~ enhancement of *β*2- or *β*3-containing receptors compared with VA, but these compounds efficaciously modulated *β*1-containing receptors, indicating a loss of *β*-subunit selectivity (see [Fig. 3, B--D](#F3){ref-type="fig"}).

### Evaluation of Anticonvulsive Effects and Potential Impairment of Locomotor Activity by VA Derivatives. {#s21}

In line with the stronger I~GABA~ enhancement by VA-A in vitro, VA-A also induced a more pronounced seizure threshold elevation compared with VA (compare [Fig. 4, A, B, and D](#F4){ref-type="fig"}). However, in contrast to VA that did not affect locomotor activity even at doses up to 30 mg/kg compared with saline-treated control animals, application of VA-A (≥10 mg/kg) significantly reduced locomotor activity. This finding suggests that VA-A, as opposed to VA, also induces sedative effects (compare [Fig. 5, A and B](#F5){ref-type="fig"}). A similar profile was observed for VA-MA: compared with VA, I~GABA~ enhancement of *β*3- and *β*2-containing receptors in vitro was more pronounced, and stronger anticonvulsive effects were also accompanied by a reduction of locomotor activity at higher doses (30 mg/kg).VA-TET displaying in vitro significantly more potent I~GABA~ enhancement of *β*3-containing receptors (efficacy comparable to VA) and more efficacious I~GABA~ enhancement of *β*2-receptors, elevated PTZ-induced seizure threshold at 10-fold lower doses than VA (VA-TET: 0.3 mg/kg: 47.3 ± 0.5 mg/kg PTZ versus VA 3 mg/kg: 47.7 ± 1.4 mg/kg PTZ ([Fig. 4C](#F4){ref-type="fig"}) but also induced the strongest reduction of locomotor activity of all tested VA derivatives at a dose of 30 mg/kg ([Fig. 5C](#F5){ref-type="fig"}). These presumably sedative effects by VA-TET were, however, observed at doses more than 100-fold higher than those required for anticonvulsive effects (0.3 mg/kg; see also [Figs. 4C](#F4){ref-type="fig"} and [5C](#F5){ref-type="fig"}).

Efficacy and potency of I~GABA~ enhancement (*α*1*β*1-3*γ*2S) by the nitrile derivative (VA-CN) did not significantly differ from that of VA. A trend toward-although not reaching statistical significance-reduced potency for *β*1- and *β*3-containing receptors compared with VA was observed ([Fig. 3A](#F3){ref-type="fig"}). However, higher doses of VA-CN (10 mg/kg) were required for seizure threshold elevation ([Fig. 4H](#F4){ref-type="fig"}) and, as opposed to VA, VA-CN also slightly reduced locomotion at high doses (30 mg/kg; [Fig. 5E](#F5){ref-type="fig"}).

Unaffected locomotor activity and either no effect on PTZ-induced seizure threshold or anticonvulsive effects occurring at rather high doses (30 mg/kg) were observed for the unselective VA derivatives (i.e., comparable efficacy and potency on *α*1*β*1-3*γ*2S receptors) VA-EA ([Figs. 4F](#F4){ref-type="fig"} and [5G](#F5){ref-type="fig"}) and VA-DEA ([Figs. 4G](#F4){ref-type="fig"} and [5H](#F5){ref-type="fig"}) and VA-DMA ([Figs. 4E](#F4){ref-type="fig"} and [5F](#F5){ref-type="fig"}).

These findings, *β*2/3-selective VA derivatives displaying anticonvulsive effects at low doses (≤10 mg/kg) and sedative effects at higher doses (≥10 mg/kg) while unselective VA derivatives (VA-EA, VA-DEA) are anticonvulsive at higher doses (30 mg/kg) without affecting locomotor activity, prompted us to probe a possible link between *β*-subunit selectivity and behavioral effects of this set of VA derivatives. Indeed, plotting maximal seizure threshold elevation (maximal effect or the effect reached at a dose of 30 mg/kg) versus the efficacy of I~GABA~ enhancement at different subunit compositions in vitro revealed a significant correlation between the compounds' efficacy at *β*3-containing receptors and anticonvulsive effects (for details, see [Supplemental Material](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.116.232983/-/DC1)). Derivatives enhancing I~GABA~ at *β*3-containing receptors more efficaciously than VA also displayed stronger protection against PTZ-induced seizures (*r =* 0.8785; *P* \< 0.01, see [Supplemental Fig. 1S](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.116.232983/-/DC1)). Conversely, efficacy at neither *β*2- nor *β*1-containing receptors correlated with the extent of seizure threshold elevation. However, VA derivatives modulating *β*2-containing receptors more efficaciously also induced more pronounced impairment of locomotor activity (*r* = −0.9262; *P* \< 0.001, [Supplemental Fig. 1S](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.116.232983/-/DC1)), whereas neither efficacy nor potency of VA and its derivatives on *β*1- or *β*3-containing receptors apparently correlated with occurring sedation. Therefore, it is tempting to speculate that the motor-impairing effects (probably sedation) of VA derivatives are determined by the interaction with *β*2-containing receptors, whereas their anticonvulsive effects might be mediated by receptors containing *β*3-subunits. This hypothesis would also be in line with previous studies highlighting the role of *β*2-containing receptors in mediating sedative effects of GABA~A~ receptor modulators such as loreclezole ([@B13]), etomidate ([@B31]; [@B42]), or even benzodiazepines ([@B1]). In contrast, anticonvulsive effects of GABA~A~ receptor ligands apparently might result from a broader, less selective GABA~A~ receptor modulation including more than a single GABA~A~ receptor subtype; Numerous work has shown that anticonvulsive effects of diazepam are only partially blunted in *α*1H101R mice, indicating that also *α*2, *α*3, and/or *α*5-containing GABA~A~ receptors could contribute to anticonvulsive effects in vivo ([@B32]; [@B23]; [@B7]; [@B10]). In addition, the *β*2/3-selective GABA~A~ receptor ligand loreclezole retained, although reduced, seizure-protecting activity in *β*2N265S mice, suggesting a complementary role for *β*3-containing receptors in mediating anticonvulsive effects ([@B13]). Most notably, the expression of *β*3-subunits is particularly high in dendritic regions of the hippocampus and dentate gyrus ([@B41]; [@B27]; [@B15]). Assuming the fundamental role of the hippocampus in seizure activity and epilepsy ([@B37]; [@B6]), amplifying GABAergic neurotransmission in the hippocampus via *β*3-containing receptors might represent an appealing approach to develop novel anticonvulsants with reduced side effects including sedation.

However, it cannot be ruled out that the observed differences in effects on PTZ-induced seizure threshold and locomotion might be also due to distinct pharmacokinetic properties (e.g., tissue distribution, penetration of the blood-brain barrier, different onset of in vivo effects, etc.). To answer this question warrants further studies. Furthermore, interaction of VA and its derivatives with targets for anticonvulsive acting drugs other than GABA~A~ receptors has not been analyzed in the present study. VA was previously reported to bind to 5-HT~5A~-receptors ([@B9]) as well as metabotropic group I/II glutamate receptors ([@B8]) and to attenuate physical and psychologic stress responses by decreasing the turnover of serotonin to 5-hydroxyindoleacetic acid and turnover of norepinephrine to 3-methoxy-4-hydroxyphenylethyleneglycol sulfate in rodent hippocampus and amygdala ([@B16]). Thus, both anticonvulsive and sedative effects of the studied compounds might also result from interactions of VA and its derivatives with multiple drug targets. [@B4] demonstrated, however, that VA's anxiolytic effect in mice is mediated exclusively by interaction with *β*3-subunit-containing GABA~A~ receptors based on their observation that VA-induced reduction of anxiety-related behavior was completely absent in *β*3N265M mice, a point mutation well-known to abolish I~GABA~ enhancement by VA and other *β*2/3-selective GABA~A~ receptor modulators ([@B13]; [@B4]). In line with this, the efficacy of the derivates on GABA~A~ receptors in vitro highly correlates with the strength of anticonvulsive effects in vivo (this study) and supports the hypothesis that these action are likely to be mediated via GABA~A~ receptors.

Taken together, our study demonstrates that modifications of VA's carboxyl function can profoundly alter potency, efficacy, and *β*-subunit selectivity of VA derivatives; replacing the carboxyl group by a tetrazole (VA-TET; see also [@B21]) as well as amidation (unsubstituted or mono-methylated amide; [@B20]; [@B21]) significantly increased efficacy and/or potency of I~GABA~ enhancement of *β*2/3-containing receptors, and, most importantly, enhanced *β*2/3-selectivity. In contrast, introduction of bulkier substituents (as ethyl for VA-EA, dimethyl for VA-DMA, or diethyl for VA-DEA) resulted in significantly increased efficacy on *β*1-containing channels and thus abolished *β*-subunit selectivity. Increased efficacy and/or potency of I~GABA~ enhancement of *β*2/3-containing receptors by VA derivatives VA-A, VA-MA, and VA-TET is likely to result in more pronounced anticonvulsive effects at low doses (≤10 mg/kg), whereas sedative effects occur at higher doses (≥10 mg/kg). In contrast, relatively high doses (30 mg/kg) of unselective VA derivatives were required for anticonvulsive effects. Our data thus suggest that VA and *β*2/3-selective VA derivatives represent interesting scaffolds for the development of novel anticonvulsants.
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ANOVA

:   analysis of variance

DMSO

:   dimethylsulfoxide

GABA~A~

:   GABA type A

I~GABA~

:   GABA-induced chloride currents

PTZ

:   pentylenetetrazole

VA

:   valerenic acid

VA-A

:   VA-amide \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-2-methylacrylamide\]

VA-CN

:   VA-nitrile \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-2-methylacrylonitrile\]

VA-DEA

:   VA-diethylamide \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N*,*N*-diethyl-2-methylacrylamide)\]

VA-DMA

:   VA-dimethylamide \[{*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N,N*,2-trimethylacrylamide)\]

VA-EA

:   VA-ethylamide \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N*-ethyl-2-methylacrylamide)\]

VA-MA

:   VA-methylamide \[(*E*)-3-((4S,7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)-*N*,2-dimethylacrylamide\]

VA-TET

:   VA-tetrazole

\[5-((*E*)-1-((4S

:   7R,7aR)-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1*H*-inden-4-yl)prop-1-en-2-yl)-1*H*-tetrazole)\]
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